Shared on27 Aug 25Fair value Decreased 3.71%
Analysts have revised Carl Zeiss Meditec's price target downward to €53.61, citing weaker-than-expected earnings, intensified competition and pricing pressures in ophthalmology, subdued recovery in elective procedures, margin compression, and persistent macroeconomic and FX headwinds. Analyst Commentary Bearish analysts are reacting to disappointing recent earnings performance, which has lagged behind expectations.
Shared on11 Aug 25Fair value Decreased 8.63%
The downward revision of Carl Zeiss Meditec’s consensus price target primarily reflects reduced revenue growth forecasts, with fair value lowered from €60.93 to €56.87 per share. What's in the News ZEISS Medical Technology’s CLARUS 700 received NMPA approval in China, enhancing advanced retinal diagnostics with ultra-widefield, high-resolution imaging.
Shared on23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Increased 1.03%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 4.29%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Increased 1.83%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on12 Mar 25Fair value Decreased 5.48%
AnalystConsensusTarget has decreased future PE multiple from 24.0x to 20.3x.